The rat endometrial adenocarcinoma cell line RUCA-I: A novel hormone-responsive in vivo/in vitro tumor model

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 1, 1996, Pages 103-115

  Vollmer, Günter ^a   Schneider, Martin R ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; TAMOXIFEN; UNCLASSIFIED DRUG; ZK 119010;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVARIECTOMY; RAT; TUMOR MODEL;

EID: 0030130518     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00012-X     Document Type: Article

References (37)

1. 1. Dallenbach-Hellweg G.: Histopathology of the endometrium. Springer, New York (1987) 55-86.
2. 2. Quarmby V. E. and Korach K. S.: Influence of 17β-estradiol on patterns of cell division in the uterus. Endocrinology 114 (1984) 694-702.
3. 3. Swenerton K. D.: Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treatment Reports 64 (1980) 805-811.
4. 4. Jordan V. C.: Overview from the international conference on long-term tamoxifen therapy for breast cancer. J. NCI 4 (1992) 231-234.
5. 5. Horvath G., Stendahl U., Kalling M., Ferno M., Himmelmann A. and Hajba A.: Antiestrogen treatment of advanced and recurrent carcinoma corpus uteri - a phase-II study of toremifene. Anticancer Research 10 (1990) 323-326.
6. 6. Fornander T., Rutquist L. E., Cedermark B., Glas U., Mattson A., Silversward J. D., Skoog L., Somell A., Theve T., Wilking N., Askergren J. and Hjolmar M. L.: Adjuvant tamoxifen in early breast cancer: occurence of new primary cancers. Lancet I (1989) 117-120.
7. 7. Galman M. S., Sundstrom S. A. and Lyttle C. R.: Antagonism of estrogen and antiestrogen-induced uterine complement component C3 expression by ICI 164384. J. Steroid Biochem 36 (1990) 281-286.
8. 8. Dukes M., Waterton J. C. and Wakeling A. E.: Antiuterotrophic effect of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J. Endocrinol. 138 (1993) 203-209.
9. 9. Dukes M., Chester R., Yarwood L. and Wakeling A. E.: Effects of a non-steroidal pure antioestogen, ZM 189,154, on oestrogen target organs of the rat including bones. J. Endocrinol. 141 (1994) 335-341.
10. 10. von Angerer E., Knebel N., Kager M. and Ganss B.: 1-Aminoalkyl-2-phenylindoles as novel pure estrogen antagonists. J. Med. Chem. 33 (1991) 2635-2640.
11. 11. Horn D. W., Vollmer G., Deerberg F. and Schneider M. R.: The EnDA endometrial carcinoma: an oestrogen-sensitive, metastasizing, in vivo tumour model of the rat. J. Cancer Res. Clin. Oncol. 119 (1993) 450-456.
12. 12. Schütze N., Kraft V., Deerberg F., Winking H., Meitinger D., Ebert K., Knuppen R. and Vollmer G.: Functions of estrogens and anti-estrogens in the rat endometrial adenocarcinoma cell lines RUCA-I and RUCA-II. Int. J. Cancer 52 (1992) 942-949.
13. 13. Horn D. W., Vollmer G., Angerer E. V. and Schneider M. R.: Effect of the nonsteroidal antiestrogen ZK 119.010 on growth and metastasis of the EnDA endometrial carcinoma. Int. J. Cancer 58 (1994) 426-429.
14. 14. Vollmer G., Ellerbrake N., Hopert A.-C., Knauthe R., Wünsche W. and Knuppen R.: Extracellular matrix induces hormone responsiveness and differentiation in RUCA-I rat endometrial adenocarcinoma cells. J. Steroid Biochem. Molec. Biol. 52 (1995) 259-269.
15. 15. Vollmer G., Ellerbrake N., Wünsche W. and Knuppen R.: Fibronectin is an estrogen-repressed protein in rat endometrial adenocarcinoma cells.. J. Steroid Biochem. Molec. Biol. 54 (1995) 131-139.
16. 16. Wakeling A. E.: Comparative studies of the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J. Steroid Biochem. 34 (1989) 183-188.
17. 17. Wakeling A. E., Dukes M. and Bowler J.: A potent specific pure antiestrogen with clinical potency. Cancer Res. 51 (1991) 3867-3873.
18. 18. Wakeling A. E. and Bowler J.: Novel antiestrogen without partial agonist activity. J. Steroid Biochem. 31 (1988) 645-653.
19. 19. Laemmli U. K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685.
20. 20. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D. and Mitchell J. B.: Evaluation of a tetrazolium-based semiautomated calorimetric assay: assessment of radiosensitivty. Cancer Res. 47 (1987) 943-946.
21. 21. Sasani P.: Endometriosis during tamoxifen treatment. Lancet. 343 (1994) 978.
22. 22. Powles T. J. and Ashley S.: Endometriosis during tamoxifen treatment. Lancet 343 (1994) 978.
23. 23. Hardell L.: Endometriosis during tamoxifen treatment. Lancet 343 (1994) 978.
24. 24. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L. and Cronin W. M.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. NCI 86 (1994) 527-537.
25. 25. Wolf D. M. and Jordan V. C.: Gynaecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol. Oncol. 45 (1992) 118-128.
26. 26. Beck L., Mafoudi A., Mularoni A., Nocollier M. and Adessi G. L.: Progesterone stimulates sulfate uptake in subcultured endometrial epithelial cells. Molec. Cell Endocrinol. 90 (1992) 95-102.
27. 27. Sundstrom S. A., Komm B. S., Leon H. P.-d., Yi Z., Teuscher C. and Lyttle C. R.: Estrogen regulation of tissue-specific expression of complement C3. J. Biol. Chem. 264 (1989) 16941-16947.
28. 28. Sundstrom S. A., Komm B. S., Xu Q., Boundy V. and Lyttle C. R.: The stimulation of uterine complement component C3 gene expression by antiestrogens. Endocrinology 126 (1990) 1449-1456.
29. 29. Schütze N., Schneider M. R., Knuppen R. and Vollmer G.: Tamoxifen and ZK 119010 exert mixed agonistic and antagonistic effects on pS2 expression in MCF-7 breast cancer cells. Cancer Detection and Prevention 18 (1994) 479-483.
30. 30. Gronemeyer H., Benhamou B., Berry M., Boquel M. T., Gofflo D., Garcia T., Lerouge T., Metzger D., Meyer M. E., Tora L., Vergezac A. and Chambon P.: Mechanisms of antihormone action. J. Steroid Biochem. Molec. Biol. 41 (1992) 217-221.
31. 31. Berry M., Metzger D. and Chambon P.: Role of the two activating domains of the estrogen receptor in the cell-type and promoter content dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9 (1990) 2811-2819.
32. 32. Arbuckle N. D., Dauvois S. and Parker M. G.: Effects of anti-oestrogens on the DNA binding activity of oestrogen receptors in vitro. Nucl. Acid Res. 20 (1992) 3839-3844.
33. 33. Sabbah M., Gouilleux F., Sola B., Redeuilh G. and Baulieu E. E.: Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone response element. Proc. Natl. Acad. Sci. (USA) 88 (1991) 390-394.
34. 34. Fawell S. E., White R., Hoare S., Sydenham M., Page M. and Parker M. G.: Inhibition of estrogen receptor-DNA binding by the "pure" anti-estrogen ICI 164384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. (USA) 87 (1990) 390-394.
35. 35. Ignar-Trowbridge D. M., Teng C. T., Ross K. A., Parker M. G., Korach K. S. and McLachlan J. A.: Peptide growth factors elicit estrogen receptor dependent transcriptional activation on an estrogen-responsive element. Acta Neuropathol. 7 (1993) 992-998.
36. 36. Smith C. L., Conneely O. M. and O'Malley B. W.: Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc. Natl. Acad. Sci. (USA) 90 (1993) 6120-6124.
37. 37. Subramaniam M., Schmidt L. J., Crutchfield C. E. and Getz M. J.: Negative regulation of serum-responsive enhancer elements. Nature 340 (1989) 64-66.